Western Therapeutics Says Observation Phase Completed in Global Trial of Fuchs Drug K-321

MT Newswires Live

11/21

D. Western Therapeutics Institute (TYO:4576) said the observation period has finished in one of two global Phase III trials of K-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.

The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.

Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2585736199"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585736199\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585736199?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 13:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585736199","market":"sg","top_or_hot":-1,"title":"Western Therapeutics Says Observation Phase Completed in Global Trial of Fuchs Drug K-321","media":"MT Newswires Live","content":"<html><body><p> D. Western <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Institute (TYO:4576) said the observation period has finished in one of two global Phase III trials of <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.</p><p>The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.</p><p>Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Western Therapeutics Says Observation Phase Completed in Global Trial of Fuchs Drug K-321</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWestern Therapeutics Says Observation Phase Completed in Global Trial of Fuchs Drug K-321\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-11-21 13:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> D. Western <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Institute (TYO:4576) said the observation period has finished in one of two global Phase III trials of <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.</p><p>The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.</p><p>Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2585736199","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585736199","pubTimestamp":1763704348,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"D. Western Therapeutics Institute  said the observation period has finished in one of two global Phase III trials of K-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4007":"制药","WRN":"西方铜金","BK4168":"多种金属与采矿","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Western Therapeutics表示Fuchs药物K-321全球试验观察阶段已完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"WRN":1.5},"content_text":"D. Western Therapeutics Institute (TYO:4576) said the observation period has finished in one of two global Phase III trials of K-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}